Skip to main content
Erschienen in: Archives of Osteoporosis 1/2016

01.12.2016 | Original Article

Persistence with denosumab and zoledronic acid among older women: a population-based cohort study

verfasst von: Éric Tremblay, Sylvie Perreault, Marc Dorais

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

Persistence to denosumab or zoledronic acid was increased compared to oral bisphosphonates.

Introduction

Denosumab and zoledronic acid are alternative therapies to oral bisphosphonates. Few studies have assessed persistence of those agents.

Methods

Incident users of denosumab and zoledronic acid were identified using healthcare databases of public drug insurance plan of Quebec province, Canada. Patients initiating therapy between October 1, 2008, and June 30, 2013, and aged 50 years and over were eligible. A persistence rate was assessed over a 2-year period. We assess the proportion of patients receiving the second, third, and fourth injections within a specific delay of predicted time of renewal of both agents. The predictors of non-persistence were analyzed using a Cox regression model only among women.

Results

Among 12,689 incident users, 97.2 % were women. Kaplan–Meier analysis showed a slow decline of persistence after initiating zoledronic acid compared to denosumab therapy, dropping to 81.6 and 63.3 % after 1 and 2 years of follow-up using the permissive gaps of 56 days, in contrast to zoledronic acid, where persistence rate still stays at 74.8 % after 2 years of follow-up using the permissive gap of 112 days. The likelihood of non-persistence was significantly higher among new users of denosumab and zoledronic acid among older patients and year of initiation; but depression and diabetes are only predictors of non-persistence among the zoledronic group. Concomitant use of calcium and vitamin D supplements was at low level which may compromise the clinical efficacy.

Conclusion

The persistence rate to denosumab and zoledronic acid was higher to the published data of oral bisphosphonates. The second intention of treatment seems to target more severe patients which may more likely to be compliant.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95(3):1174–1181CrossRefPubMed Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95(3):1174–1181CrossRefPubMed
2.
Zurück zum Zitat Kanis JA, Johnell O, De Laet C, et al. (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382CrossRefPubMed Kanis JA, Johnell O, De Laet C, et al. (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382CrossRefPubMed
3.
Zurück zum Zitat Bessette L, Jean S, Lapointe-Garant MP, et al. (2012) Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int 23(6):1757–1768CrossRefPubMed Bessette L, Jean S, Lapointe-Garant MP, et al. (2012) Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporos Int 23(6):1757–1768CrossRefPubMed
5.
Zurück zum Zitat Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S (2009) Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int 20(9):1571–1581CrossRefPubMed Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S (2009) Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int 20(9):1571–1581CrossRefPubMed
6.
Zurück zum Zitat Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B (2013) Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci 17(5):658–667PubMed Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B (2013) Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci 17(5):658–667PubMed
7.
Zurück zum Zitat Murad MH, Drake MT, Mullan RJ, et al. (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880CrossRefPubMed Murad MH, Drake MT, Mullan RJ, et al. (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880CrossRefPubMed
8.
Zurück zum Zitat Morin S, Rahme E, Behlouli H, Tenenhouse A, Goltzman D, Pilote L (2007) Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int 18(12):1625–1632CrossRefPubMed Morin S, Rahme E, Behlouli H, Tenenhouse A, Goltzman D, Pilote L (2007) Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int 18(12):1625–1632CrossRefPubMed
9.
Zurück zum Zitat Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR (2012) Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int 23(4):1475–1480CrossRefPubMed Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR (2012) Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int 23(4):1475–1480CrossRefPubMed
10.
Zurück zum Zitat Maraka S, Kennel KA (2015) Bisphosphonates for the prevention and treatment of osteoporosis. BMJ 351:h3783CrossRefPubMed Maraka S, Kennel KA (2015) Bisphosphonates for the prevention and treatment of osteoporosis. BMJ 351:h3783CrossRefPubMed
11.
Zurück zum Zitat Blouin J, Dragomir A, Ste-Marie LG, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 92(3):887–894CrossRefPubMed Blouin J, Dragomir A, Ste-Marie LG, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 92(3):887–894CrossRefPubMed
12.
Zurück zum Zitat Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–13CrossRefPubMed Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–13CrossRefPubMed
13.
Zurück zum Zitat Siris ES, Pasquale MK, Wang Y, Watts NB (2011) Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 26(1):3–11CrossRefPubMed Siris ES, Pasquale MK, Wang Y, Watts NB (2011) Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 26(1):3–11CrossRefPubMed
14.
Zurück zum Zitat Wade SW, Curtis JR, Yu J, et al. (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50(4):870–875CrossRefPubMed Wade SW, Curtis JR, Yu J, et al. (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50(4):870–875CrossRefPubMed
15.
Zurück zum Zitat Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25–39PubMed Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25–39PubMed
16.
Zurück zum Zitat Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571–581CrossRefPubMed Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571–581CrossRefPubMed
17.
Zurück zum Zitat Siris ES, Harris ST, Rosen CJ, et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022CrossRefPubMed Siris ES, Harris ST, Rosen CJ, et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022CrossRefPubMed
18.
Zurück zum Zitat Curtis JR, Yun H, Matthews R, Saag KG, Delzell E (2012) Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 64(7):1054–1060 Curtis JR, Yun H, Matthews R, Saag KG, Delzell E (2012) Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 64(7):1054–1060
19.
Zurück zum Zitat Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015.
20.
Zurück zum Zitat Hughes C (2010) ICD-9 update 2011: approaching the change to ICD-10. Fam Pract Manag 17(5):15–16PubMed Hughes C (2010) ICD-9 update 2011: approaching the change to ICD-10. Fam Pract Manag 17(5):15–16PubMed
22.
Zurück zum Zitat Moride Y, Abenhaim L (1994) Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47(7):731–737CrossRefPubMed Moride Y, Abenhaim L (1994) Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47(7):731–737CrossRefPubMed
23.
Zurück zum Zitat Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48(8):999–1009CrossRefPubMed Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48(8):999–1009CrossRefPubMed
24.
Zurück zum Zitat Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M (2000) Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 53(2):183–194CrossRefPubMed Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M (2000) Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 53(2):183–194CrossRefPubMed
25.
Zurück zum Zitat Wilchesky M, Tamblyn RM, Huang A (2004) Validation of diagnostic codes within medical services claims. J Clin Epidemiol 57(2):131–141CrossRefPubMed Wilchesky M, Tamblyn RM, Huang A (2004) Validation of diagnostic codes within medical services claims. J Clin Epidemiol 57(2):131–141CrossRefPubMed
26.
Zurück zum Zitat Hudson M, Avina-Zubieta A, Lacaille D, Bernatsky S, Lix L, Jean S (2013) The validity of administrative data to identify hip fractures is high—a systematic review. J Clin Epidemiol 66(3):278–285CrossRefPubMed Hudson M, Avina-Zubieta A, Lacaille D, Bernatsky S, Lix L, Jean S (2013) The validity of administrative data to identify hip fractures is high—a systematic review. J Clin Epidemiol 66(3):278–285CrossRefPubMed
27.
Zurück zum Zitat Silverman SL, Siris E, Kendler DL, et al. (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26(1):361–372CrossRefPubMed Silverman SL, Siris E, Kendler DL, et al. (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26(1):361–372CrossRefPubMed
28.
Zurück zum Zitat Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574 discussion 575-567CrossRefPubMed Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574 discussion 575-567CrossRefPubMed
29.
Zurück zum Zitat Hadji P, Papaioannou N, Gielen E, et al. (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26(10):2479–2489CrossRefPubMedPubMedCentral Hadji P, Papaioannou N, Gielen E, et al. (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26(10):2479–2489CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Cadarette SM, Levesque L, Mamdani M, et al. (2013) Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open 1(3):E97–E105CrossRefPubMedPubMedCentral Cadarette SM, Levesque L, Mamdani M, et al. (2013) Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open 1(3):E97–E105CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66(1):117–127CrossRefPubMedPubMedCentral Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S (2008) Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 66(1):117–127CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Papaioannou A, Morin S, AM C, et al. (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873CrossRefPubMedPubMedCentral Papaioannou A, Morin S, AM C, et al. (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23(3):1075–1082CrossRefPubMed Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23(3):1075–1082CrossRefPubMed
34.
Zurück zum Zitat Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23(9):2329–2333CrossRefPubMed Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23(9):2329–2333CrossRefPubMed
35.
Zurück zum Zitat Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411CrossRefPubMedPubMedCentral Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Foundation NO. Clinicians’s guide to prevention and treatment of osteoporosis. 2013. Foundation NO. Clinicians’s guide to prevention and treatment of osteoporosis. 2013.
37.
Zurück zum Zitat Schousboe JT (2013) Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep 11(1):21–29CrossRefPubMed Schousboe JT (2013) Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep 11(1):21–29CrossRefPubMed
38.
Zurück zum Zitat Overman RA, Gourlay ML, Deal CL. Adherence to denosumab in a large healthcare system. Arthritis and Rheumatology. Vol 66 2014:S1011. Overman RA, Gourlay ML, Deal CL. Adherence to denosumab in a large healthcare system. Arthritis and Rheumatology. Vol 66 2014:S1011.
40.
Zurück zum Zitat West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142(10):1103–1112PubMed West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142(10):1103–1112PubMed
Metadaten
Titel
Persistence with denosumab and zoledronic acid among older women: a population-based cohort study
verfasst von
Éric Tremblay
Sylvie Perreault
Marc Dorais
Publikationsdatum
01.12.2016
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2016
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-016-0282-3

Weitere Artikel der Ausgabe 1/2016

Archives of Osteoporosis 1/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.